253 related articles for article (PubMed ID: 36117109)
1. Mechanisms of PDAC subtype heterogeneity and therapy response.
Espinet E; Klein L; Puré E; Singh SK
Trends Cancer; 2022 Dec; 8(12):1060-1071. PubMed ID: 36117109
[TBL] [Abstract][Full Text] [Related]
2. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.
Park JK; Jeong HO; Kim H; Choi JH; Lee EM; Kim S; Jang J; Choi DW; Lee SH; Kim KM; Jang KT; Lee KH; Lee KT; Lee MW; Lee JK; Lee S
Mol Cancer; 2024 May; 23(1):87. PubMed ID: 38702773
[TBL] [Abstract][Full Text] [Related]
3. Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions.
Palma AM; Vudatha V; Peixoto ML; Madan E
Adv Cancer Res; 2023; 159():203-249. PubMed ID: 37268397
[TBL] [Abstract][Full Text] [Related]
4. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
5. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
[TBL] [Abstract][Full Text] [Related]
6. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment.
Werba G; Weissinger D; Kawaler EA; Zhao E; Kalfakakou D; Dhara S; Wang L; Lim HB; Oh G; Jing X; Beri N; Khanna L; Gonda T; Oberstein P; Hajdu C; Loomis C; Heguy A; Sherman MH; Lund AW; Welling TH; Dolgalev I; Tsirigos A; Simeone DM
Nat Commun; 2023 Feb; 14(1):797. PubMed ID: 36781852
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies.
Kuznetsova A; Popova O; Panchenkov D; Dyuzheva T; Ivanov A
Clin Exp Med; 2023 Jul; 23(3):619-643. PubMed ID: 36085429
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment.
Boyd LNC; Andini KD; Peters GJ; Kazemier G; Giovannetti E
Semin Cancer Biol; 2022 Jul; 82():184-196. PubMed ID: 33737108
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
10. Epigenetic therapeutic strategies in pancreatic cancer.
Orlacchio A; Muzyka S; Gonda TA
Int Rev Cell Mol Biol; 2024; 383():1-40. PubMed ID: 38359967
[TBL] [Abstract][Full Text] [Related]
11. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression.
Chen K; Wang Q; Li M; Guo H; Liu W; Wang F; Tian X; Yang Y
EBioMedicine; 2021 Apr; 66():103315. PubMed ID: 33819739
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
13. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
[TBL] [Abstract][Full Text] [Related]
14. Stabilization of the classical phenotype upon integration of pancreatic cancer cells into the duodenal epithelium.
Bozóky B; Fernández Moro C; Strell C; Geyer N; Heuchel RL; Löhr JM; Ernberg I; Szekely L; Gerling M; Bozóky B
Neoplasia; 2021 Dec; 23(12):1300-1306. PubMed ID: 34798385
[TBL] [Abstract][Full Text] [Related]
15. Regulation of pancreatic cancer therapy resistance by chemokines.
Gautam SK; Basu S; Aithal A; Dwivedi NV; Gulati M; Jain M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):69-80. PubMed ID: 36064086
[TBL] [Abstract][Full Text] [Related]
16. Altered histone acetylation patterns in pancreatic cancer cell lines induce subtype‑specific transcriptomic and phenotypical changes.
Zhou Q; Pichlmeier S; Denz AM; Schreiner N; Straub T; Benitz S; Wolff J; Fahr L; Del Socorro Escobar Lopez M; Kleeff J; Mayerle J; Mahajan UM; Regel I
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38240084
[TBL] [Abstract][Full Text] [Related]
17. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer.
Ruta V; Naro C; Pieraccioli M; Leccese A; Archibugi L; Cesari E; Panzeri V; Allgöwer C; Arcidiacono PG; Falconi M; Carbone C; Tortora G; Borrelli F; Attili F; Spada C; Quero G; Alfieri S; Doglioni C; Kleger A; Capurso G; Sette C
Cell Rep Med; 2024 Feb; 5(2):101411. PubMed ID: 38325381
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma.
Peng J; Sun BF; Chen CY; Zhou JY; Chen YS; Chen H; Liu L; Huang D; Jiang J; Cui GS; Yang Y; Wang W; Guo D; Dai M; Guo J; Zhang T; Liao Q; Liu Y; Zhao YL; Han DL; Zhao Y; Yang YG; Wu W
Cell Res; 2019 Sep; 29(9):725-738. PubMed ID: 31273297
[TBL] [Abstract][Full Text] [Related]
19. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses.
Shinkawa T; Ohuchida K; Mochida Y; Sakihama K; Iwamoto C; Abe T; Ideno N; Mizuuchi Y; Shindo K; Ikenaga N; Moriyama T; Nakata K; Oda Y; Nakamura M
J Exp Clin Cancer Res; 2022 Mar; 41(1):89. PubMed ID: 35272688
[TBL] [Abstract][Full Text] [Related]
20. [Epithelial-stromal interactions in pancreatic adenocarcinoma: the role of stroma in disease progression].
Kuznetsova AV; Popova OP; Astakhov DA; Ivanov YV; Panchenkov DN; Ivanov AA
Arkh Patol; 2022; 84(5):65-70. PubMed ID: 36178225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
